ArticleOpen veterinary journal2025
Electrochemotherapy for canine prostatic carcinoma treatment.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Canine prostatic carcinoma (PC) is an uncommon neoplasia characterized by aggressive biological behavior. Treatment options include surgery (partial or total prostatectomy), radiation therapy (RT), and medical treatment [non-steroidal anti-inflammatory drugs (NSAIDs), chemotherapy, or tyrosine kinase inhibitors]. Electrochemotherapy (ECT) is a local treatment modality increasingly used in human and veterinary oncology. Aim: This retrospective multi-institutional study aimed to assess the safety, feasibility, and preliminary efficacy of ECT as a treatment for canine PC. Methods: Dogs with cytologically or histologically confirmed PC treated with ECT as first-line therapy were included in this study. Dogs with distant metastases or those previously treated with surgery, RT, or chemotherapy were excluded. The clinical response was evaluated based on the improvement of clinical signs and reduction in tumor volume. Adverse effects, time to progression, and median survival time (MST) were recorded. Results: Nine dogs were enrolled in this study. All but two dogs were neutered. Regional lymph node metastases were present in two patients (22%). Metastatic lymph nodes were treated concurrently with ECT in one patient. Three patients (33%) had a partial response, three (33%) had stable disease, 2 (22%) had progressive disease, and one had a complete response. The overall response rate, including complete and partial responses, was 44%. The median TTP was 74 days, and MST was 70 days. The treatment was well tolerated, with no observed local or systemic adverse effects. Conclusion: This preliminary study showed that ECT is a safe and well-tolerated local therapy, although survival outcomes were modest compared with those of surgery, RT, or medical treatment. Further controlled, prospective studies are needed to better define its role as a therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.